Lexaria Bioscience Corp. set to benefit from increasing interest in CBD as patented technology improves taste, rapidity and effectiveness of bioactive compounds including cannabinoids

A new scientific review of the safety and side effects of cannabidiol confirms and expands on the myriad known health benefits of cannabidiol and the compound’s lack of side effects.

The review, titled “An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies,” was published in the journal Cannabis and Cannabinoid Research in June. To view the full publication, visit: http://dtn.fm/cbd-clinical-overview-pdf.

Cannabidiol has a number of beneficial effects, the study states; it is anti-inflammatory, anxiolytic, antiemetic and antipsychotic. This can only increase the demand for cannabidiol (CBD) products and is good news for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP). Lexaria has patented a revolutionary lipophilic delivery method which allows accurate, timely delivery of cannabinoids without the need for users to smoke, vape or otherwise inhale the substance.

Lexaria out-licenses its proprietary technology for improved taste, increased speed and efficiency in the delivery of bioactive compounds, including cannabinoids. The special manufacturing process infuses CBD within lipids, which form the basis of the human endocannabinoid system. Lexaria Bioscience’s new process masks the undesirable taste of cannabidiol, which eliminates the need for added sugar and results in a healthier product.

The review’s authors, Iffland Kerstin and Grotenhermen Franjo, concluded that along with the beneficial effects, the safety profile of CBD is excellent. Chronic use and high doses of up to 1,500 mg per day have repeatedly shown to be well tolerated. Cannabidiol does not alter physiological parameters such as heart rate and blood pressure and does not adversely affect psychological and psychomotor functions, food intake or gastrointestinal transit.

The study’s authors reviewed clinical data and animal studies to extend and update a comprehensive survey by Bergamaschi et al. in 2011 on CBD safety and side effects; they concluded that CBD has a much better side effect profile than other drugs used for the treatment of epilepsy and psychotic disorders.

Several studies have shown cannabidiol to be effective in the treatment of epilepsy. In one study, CBD treatment reduced seizures by 45% in 261 young children who were not receiving relief from standard medications. In another study, CBD reduced the frequency of seizures by 39% in therapy-resistant epilepsy patients.

Cannabidiol has also been shown to have anti-anxiety effects equivalent to a standard dose of imipramine, a selective serotonin reuptake inhibitor sold as Tofranil and commonly used to treat anxiety and depression.

Studies have found that CBD reduces inflammation in the gastrointestinal system, treats symptoms of multiple sclerosis and helps with the management of glaucoma.

According to the study review, cannabidiol has also been shown to:

help with cannabis withdrawal

reduce heroin-seeking behaviors

reduce psychotic symptoms in Parkinson’s patients

reduce the likelihood of developing diabetes

positively modulate the immune system in diseases such as multiple sclerosis, arthritis and diabetes

reduce amyloid beta neuro-inflammation and prevent the development of a social recognition deficit in Alzheimer’s disease.

reduce swelling and inflammation in arthritis

prevent or slow the spread of certain types of aggressive cancer cells

reduce weight gain

reduce symptoms of psychiatric disorders such as psychosis and bipolar disorder

Cannabidiol is not the only substance which can be formulated and delivered via Lexaria’s revolutionary delivery method; the patented technology can be used for delivery of nicotine, vitamins, analgesics and a variety of other substances. Tests by an independent, third-party lab show that Lexaria’s technological process and lipid formulation improve intestinal absorption by as much as 500%.

Patents have been issued to the company in the U.S. and Australia protecting Lexaria’s intellectual property for the edible delivery of all non-psychoactive cannabinoids, including cannabinoid edibles. A variety of food and beverage formats are protected by the patent, including tea, coffee, cocoa powder, fresh foods and meats, dairy products, pastas, breads, seeds, nuts, spices, herbs, candies, flavorings and more.

Lexaria is primarily a B2B enterprise, and it is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the U.S., and abroad.

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.